HighTower Advisors
SYRS

HighTower Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

HighTower Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,898
Closed -$3.42K – 4099
2024
Q4 		$3.42K Hold
14,898
– – ﹤0.01% 3647
2024
Q3 		$32K Sell
14,898
-450
-3% -$1.62K ﹤0.01% 3466
2024
Q2 		$79K Buy
15,348
+431
+3% +$2.27K ﹤0.01% 3251
2024
Q1 		$80K Sell
14,917
-87
-0.6% -$602 ﹤0.01% 3198
2023
Q4 		$117K Hold
15,004
– – ﹤0.01% 3164
2023
Q3 		$59K Hold
15,004
– – ﹤0.01% 3201
2023
Q2 		$47K Hold
15,004
– – ﹤0.01% 3171
2023
Q1 		$40K Hold
15,004
– – ﹤0.01% 3074
2022
Q4 		$53K Buy
+15,004
New +$65.1K ﹤0.01% 3027

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HighTower Advisors's SYRS Position: Q1 2025 in Review

HighTower Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 14,898 shares — an estimated $3.42K sold.

HighTower Advisors first reported a position in SYRS in Q4 2022 and held it in 9 quarters. The position peaked at $117K in Q4 2023. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • HighTower Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • HighTower Advisors sold 14,898 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $3.42K.
  • HighTower Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 9 quarters.
  • HighTower Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $117K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.